• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Celularity Appoints Industry Leader Diane Parks to its Board of Directors

    6/3/22 8:00:00 AM ET
    $CALT
    $CELU
    $CTIC
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALT alert in real time by email

    FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.).

    "It is with great pleasure we welcome Diane to the Celularity Board of Directors during this exciting time of growth at the company," said Robert J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive Officer of Celularity. "Building on our achievement of multiple transformational milestones, we believe Diane's significant track record of driving profitable growth and commercialization strategies adds important Board-level expertise to the guidance and oversight of our clinical and preclinical cellular therapy programs."

    Ms. Parks, commented, "I am very excited to join Celularity's Board of Directors and to help guide one of the most promising and innovative approaches to cellular therapeutics. I look forward to bringing my commercial experience and passion to Celularity, and to partnering with its incredibly talented management team to deliver potentially life-changing therapies to patients in need."

    Ms. Parks joins the Celularity Board of Directors with more than 30 years of commercial experience in the pharmaceutical and biotechnology industries. Most recently, she served as Senior Vice President, Head of U.S. Commercial for Kite Pharma, Inc. (acquired by Gilead Sciences, Inc. for $11.9 billion), where she developed and executed the strategic plan for the commercial launch of Yescarta®, the first CAR-T therapy approved for large B-cell lymphoma. Previously, Ms. Parks served as Vice President, Head of Global Marketing for Pharmacyclics, Inc. (acquired by AbbVie Inc.  for $21 billion), where she was responsible for the marketing strategy and launch of Imbruvica®. Before that, she served as Vice President, Sales for Amgen Inc., where she successfully led the Hospital and Nephrology sales teams. In addition, she served as Senior Vice President, Specialty Biotherapeutics and Managed Care for Genentech, Inc. (acquired by Roche  Holdings, Inc. for $46.8 billion). She currently serves on the boards of Calliditas Therapeutics AB (NASDAQ:CALT), CTI BioPharma Corp. (NASDAQ:CTIC), Kura Oncology, Inc. (NASDAQ:KURA),  Soligenix, Inc.  (NASDAQ:SNGX), and TriSalus Life Sciences and the Lymphoma Research Foundation. Ms. Parks earned an MBA from Georgia State University and a BS from Kansas State University.

    Celularity also announced today that Jay R. Bloom resigned from the Board of Directors. "I want to thank Jay for his service as a Celularity director during the transition from special purpose acquisition company through the business combination with Celularity, and for his advice and guidance during this important period for the company," said Hariri.

    About Celularity 

    Celularity, Inc. (NASDAQ:CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta's unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

    To learn more, visit celularity.com

    Celularity Media/Investor Contact:

    Carlos Ramirez, SVP Investor Relations

    Celularity

    [email protected]



    Primary Logo

    Get the next $CALT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CALT
    $CELU
    $CTIC
    $KURA

    CompanyDatePrice TargetRatingAnalyst
    Kura Oncology Inc.
    $KURA
    9/4/2025Neutral
    Guggenheim
    Kura Oncology Inc.
    $KURA
    2/6/2025Buy → Neutral
    BTIG Research
    Kura Oncology Inc.
    $KURA
    10/24/2024$27.00Buy
    UBS
    Kura Oncology Inc.
    $KURA
    10/14/2024$26.00 → $19.00Buy → Hold
    Stifel
    Kura Oncology Inc.
    $KURA
    12/22/2023$26.00Buy
    Mizuho
    Kura Oncology Inc.
    $KURA
    8/11/2023$31.00Buy
    BofA Securities
    Kura Oncology Inc.
    $KURA
    7/27/2023$10.50Sector Perform
    Scotiabank
    Calliditas Therapeutics AB
    $CALT
    6/20/2023$60.00Buy
    H.C. Wainwright
    More analyst ratings

    $CALT
    $CELU
    $CTIC
    $KURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lim Kok Thay bought $5,331,335 worth of shares (21,410,983 units at $0.25) (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    1/17/24 5:22:20 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hariri Robert J bought $2,984,294 worth of shares (18,422,124 units at $0.16), increasing direct ownership by 182% to 28,570,434 units (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    10/10/23 9:48:11 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALT
    $CELU
    $CTIC
    $KURA
    SEC Filings

    View All

    SEC Form 10-Q filed by Celularity Inc.

    10-Q - Celularity Inc (0001752828) (Filer)

    8/29/25 5:21:03 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Celularity Inc.

    10-Q - Celularity Inc (0001752828) (Filer)

    8/29/25 5:17:51 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    8/18/25 4:30:34 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALT
    $CELU
    $CTIC
    $KURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on September 2, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 82,950 shares of common stock to seven (7) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq L

    9/5/25 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

    September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806 SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, today announced it will host two virtual investor and analyst events to spotlight its innovative farnesyl transferase inhibitor (FTI) program. These events will underscore Kura's leadership in targeting cancer signaling pathways to address unmet needs in solid tu

    9/3/25 8:02:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

    Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1). FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and its Quarterly Report on Form 10-Q for the qua

    9/3/25 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALT
    $CELU
    $CTIC
    $KURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kura Oncology Inc.

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    8/14/25 4:05:05 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Large owner Lim Kok Thay

    4 - Celularity Inc (0001752828) (Issuer)

    7/28/25 9:40:50 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Levien Vincent

    4 - Celularity Inc (0001752828) (Issuer)

    7/28/25 4:30:06 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALT
    $CELU
    $CTIC
    $KURA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALT
    $CELU
    $CTIC
    $KURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Kura Oncology

    Guggenheim initiated coverage of Kura Oncology with a rating of Neutral

    9/4/25 9:01:23 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology downgraded by BTIG Research

    BTIG Research downgraded Kura Oncology from Buy to Neutral

    2/6/25 7:53:07 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Kura Oncology with a new price target

    UBS initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $27.00

    10/24/24 6:23:30 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALT
    $CELU
    $CTIC
    $KURA
    Financials

    Live finance-specific insights

    View All

    Kura Oncology Reports Second Quarter 2025 Financial Results

    – FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – KOMET-017-IC (intensive chemotherapy) and NIC (non-intensive chemotherapy) phase 3 studies in newly diagnosed AML on track to start in 2H 2025 – – Three clinical abstracts from Kura's farnesyl transferase inhibitors (FTI) development program accepted for presentation at the 2025 ESMO Congress – – $630.7 million in pro forma cash, together with anticipated collaboration agreement payments, expected to supp

    8/7/25 4:05:00 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology to Report Second Quarter 2025 Financial Results

    SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second quarter 2025 financial results after the close of U.S. financial markets on Thursday, August 7, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ2. A live webcast and archived rep

    7/31/25 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports First Quarter 2025 Financial Results

    – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

    5/1/25 4:05:00 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALT
    $CELU
    $CTIC
    $KURA
    Leadership Updates

    Live Leadership Updates

    View All

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

    – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

    10/29/24 8:00:00 AM ET
    $AMAM
    $KURA
    $RNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

    SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. "On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "His extensive experience in R&D and regulatory aff

    9/17/24 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALT
    $CELU
    $CTIC
    $KURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Kura Oncology Inc.

    SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

    12/5/24 6:55:37 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

    SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    11/14/24 4:31:29 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

    SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    11/14/24 4:32:22 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care